Kolding: It lived up to all our criteria

Novo A/S wants to continue the good development in newly purchased company Sonion, which matches the company’s strategy perfectly, says CEO Eivind Kolding. The acquisition is, however, not to be seen as a sign that the holding company is moving away from the biotech sector, he says.


In a matter of days, Novo A/S has shedded a biotech company and assumed control of a medtech company, but CEO Eivind Kolding denies speculation that the investment group behind Novo Nordisk and Novozymes is moving away from biotech altogether. It is rather a matter of Novo being able to tick off all its criteria for new acquisitions.

The newest member of the Novo family, Sonion, is a global market leader within micro acoustic components for use in hearing instruments, and the company fits Novo’s new strategy like a glove.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch


Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier